Clicky

Verici Dx Plc(VRCDF)

Description: Verici Dx plc, an immuno-diagnostics development company, focuses on the kidney transplantation market. The company develops prognostic and diagnostic tests for kidney transplant patients. Its in-development tests include Clarava, a pre-transplant prognosis test for the risk of early acute rejection; Tuteva, a post-transplant test that focuses on acute cellular rejection; and Protega, a liquid biopsy that aims to predict the risk of fibrosis and long-term graft failure. The company was incorporated in 2020 and is based in Penarth, the United Kingdom.


Keywords: Medicine Clinical Medicine Transplantation Diagnostic Tests Fibrosis Transplantation Medicine Biopsy Organ Transplantation Kidney Transplant Transplant Rejection Kidney Transplantation Immune System Disorders

Home Page:

Exchange: US

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 0
Price-to-Sales TTM: 0
IPO Date:
Fiscal Year End: December
Full Time Employees: 14
Back to stocks